Prana raises US$3.7 million

By Staff writer
Wednesday, 08 December, 2004

A number of US institutional investors have purchased and exercised 9.5 million options in Prana Biotechnology (NASDAQ: PRAN, ASX: PBT) at $0.50 per share, raising US$3.7 million for the company.

The options - originally owned by directors and insiders of Prana - were exercised prior to their scheduled expiry date of December 1, 2004.

The exercise of options increases the total issued shares in Prana to 126,890,821.

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Content from other channels on our network

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Sustainable wastewater treatment achieved for urban areas

'Brownfielding' increases to meet metal demand

NSW to exceed energy storage targets

Health Star Ratings set to become regulated in Australia and NZ

Fast detection of food contamination using enhanced AI tool

Abattoir safety program in WA raises more awareness

Closing the loop with food packaging made from fish skin waste

Electric trucks hit the road to deliver beer in Perth

Why physical device security is becoming a patient privacy issue in health care

Food waste in Australian hospitals and aged care homes — can AI help?

Legislation introduced to improve private health choice and transparency

WA healthcare professionals gain workplace-specific courses

InterSystems Honoured with Four 2026 Best in KLAS Awards